The EAN Scientific Committee has established a Task Force dedicated to Rare Neurological Diseases (RNDs), with the aim of helping patients with RNDs and their families, through raising awareness to facilitate earlier diagnosis, timely management and coordinating research.
The non-profit organization BioPontis Alliance for Rare Diseases (BioPontis) is dedicated to help in developing novel medicines for rare neurological disorders, most of which are genetic in origin. This requires innovation in therapeutic approaches, leading edge knowledge of neuroscience, genomics, clinical neurology, therapeutics development, and regulatory sciences.
BioPontis and the EAN have both expressed interest in working together and have been in contact regarding potential collaborations.
Recently, BioPontis has unveiled the names of the members of its newly formed Scientific Advisory Committee. The Board of Directors has sought a panel of experts with in-depth knowledge in the areas mentioned above. The six external and two internal appointees convened at the inaugural meeting last September. They agreed to focus on the treatment of the most devastating and debilitating rare disorders.
It is with great pleasure that we inform you that Prof. Antonio Federico, Chair of the EAN Scientific Committee, has been appointed as a member of the BioPontis Scientific Advisory committee.
by Prof. David Vodušek, Chair of the EAN Liaison Committee
Further information on this committee is available here.
